Anavex Life Sciences Corp. (AVXL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Anavex Life Sciences Corp... (AVXL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

10.46

-0.09 (-0.85%)

At close: Jan 14, 2025, 3:59 PM

10.63

1.67%

Pre-market Jan 15, 2025, 07:56 AM EST

undefined% (undefined)

Bid	10.52
Market Cap	886.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.52
PE Ratio (ttm)	-20.11
Forward PE	n/a
Analyst	Buy

Ask	10.63
Volume	1,490,003
Avg. Volume (20D)	1,832,455
Open	10.58
Previous Close	10.55
Day's Range	10.19 - 10.89
52-Week Range	3.25 - 14.44
Beta	undefined

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 2, 2006

Employees 40

Stock Exchange NASDAQ

Ticker Symbol AVXL

Website https://www.anavex.com

Analyst Forecast

According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 339.98% from the latest price.

Buy 66.67%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago · Source

+29.55%

Anavex Life Sciences shares are trading higher aft... Unlock content with Pro Subscription

2 months ago · Source

+6.73%

Anavex Life Sciences shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

News

3 days ago · seekingalpha.com

Playing The Odds Of Anavex Alzheimer's Drug Approval

The EMA has accepted Anavex's Alzheimer's drug Blarcamesine for evaluation, with a decision expected by December 2025. Blarcamesine shows a 92% likelihood of approval by the EMA, yet investors have no...

1 week ago · zacks.com

Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)

Anavex Life Sciences (AVXL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it...

2 weeks ago · zacks.com

Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?

Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.

2 weeks ago · zacks.com

All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy

Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago · seekingalpha.com

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and functional decline, and an attractive safety profile. The EMA has accepted ANAVEX...

2 weeks ago · marketbeat.com

Short-Squeeze Target Anavex Life Sciences Gains Traction

Anavex Life Sciences NASDAQ: AVXL is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into th...

3 weeks ago · seekingalpha.com

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, ...

3 weeks ago · seekingalpha.com

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2024 Earnings Call Transcript December 23, 2024 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenis...

3 weeks ago · investopedia.com

What To Expect in the Markets This Week

Markets will trade on shortened hours during the Christmas holiday week, with all markets closed Wednesday for the holiday, and shortened trading hours on Christmas Eve.

1 month ago · https://www.marketscreener.com

North American Morning Briefing : Global Ad Shares -2-

Lundin Mining Announces Sale to Boliden of its Neves-Corvo operation in Portugal and Zinkgruvan operation in Sweden for Up to $1.52 Billion: Lundin To Receive Upfront Cash Consideration of $1.37B Upon...

2 months ago · seekingalpha.com

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Anavex Life Sciences' stock surged on new Alzheimer's trial data, but the data's inconsistency raises concerns, making the company a Hold rating. Despite some promising cognitive results, the lack of ...